Neurology® Podcast

In the first segment, Dr. Stacey Clardy talks with Dr. Daniel Hartung about whether closing the Part D coverage gap between 2010-2019 lowered patients' out-of-pocket costs for multiple sclerosis drugs. In the second part of the podcast, Dr. Teshamae Monteith discusses sex, exercise, and other benign causes of thunderclap headache with Dr. Jonathan Smith in the final part of our four-part series on...

In the first segment, Dr. Jason Crowell talks with Dr. Paul Ford about patient perceptions of the FDA approval process for disease modifying therapies in people living with multiple sclerosis. In the second part of the podcast, Dr. Teshamae Monteith discusses the management of cerebral aneurysm with Dr. Dileep Yavagal in the third part of our four-part series on thunderclap headache.

In the first segment, Dr. Halley Alexander talks with Dr. Pia De Stefano about the safety and efficacy of artificial coma induction in the treatment of status epilepticus. In the second part of the podcast, Dr. Teshamae Monteith discusses a case presentation of RCVS and clinical management with Dr. Andy Southerland and his patient, Martien Halvorson-Taylor, in the second part of our four-part seri...

In the first segment, Dr. Jon Stone talks with Dr. Anne Sofie Hansen about the spectrum and risk of psychiatric disorders in childhood-onset psychogenic nonepileptic seizures. In the second part of the podcast, Dr. Teshamae Monteith discusses ten causes of thunderclap headache and presentation with Dr. Alexandra Cocores in the first part of our four-part series on thunderclap headache. Disclosures...

This month's replay of past episodes showcases a selection of interviews concerning the FDA approval of aducanumab for the treatment of Alzheimer disease from clinical, political, and economic perspectives. The selected interviews feature conversations between Dr. Gregg Day and Pam Belluck, Dr. Jeff Burns and Dr. Ron Peterson, Dr. Jason Crowell and Dr. Steve Pearson, and Dr. Jeff Burns and Dr. Dan...

Dr. Stacey Clardy discusses the impact of surgical approaches to thymectomy upon remission rates in myasthenia gravis with Dr. Joseph Shrager.

In the first segment, Will Rondeau discusses the symptoms, incidence, and resource utilization of reversible cerebrovascular vasoconstriction syndrome with Dr. Jessica Magid-Bernstein. In the second part of the podcast, Dr. Andy Southerland discusses the optimization of atrial fibrillation treatment and stroke prevention with Dr. Seemant Chaturvedi.

In the first segment, Dr. Alex Menze talks with Dr. Clifford Saper about Havana Syndrome and recent attacks on American diplomats. In the second part of the podcast, Dr. Jeff Ratliff discusses the natural history of afferent baroreflex failure with Dr. Guillaume Lamotte.

In the first segment, Dr. Gregg Day speaks with Dr. Josep Dalmau about NMDAR antibodies in patients with first episode psychosis and the utility of criteria for autoimmune psychosis. In the second part of the podcast, Dr. Jeff Burns talks to neurologist Dr. Daniel Gibbs about his Alzheimer's disease diagnosis and experience participating in a clinical trial for aducanumab.

This month's replay of past episodes showcases a selection of interviews on the impact of pregnancy on various neurologic disorders, featuring Drs. Page Pennell, Paula Emanuela Voinescu, Mary Angela O'Neal, Emma Ciafaloni, Raed Alroughani, Rae Bacharach, Annette Langer-Gould, Nicolas Collongues, and Petra Ijäs.

This second installment in our two-part series features Dr. Stacey Clardy in conversation with Mary Post, CEO of the American Academy of Neurology.

Dr. Gregg Day speaks with Pam Belluck, an award-winning journalist at the New York Times, about her coverage of the recent FDA approval of aducanumab for Alzheimer disease treatment.

This first installment of a 2-part series features Dr. Stacey Clardy in conversation with Mary Post, CEO of the American Academy of Neurology. 

Dr. Jeff Burns, Director of the University of Kansas Alzheimer's Disease Center, speaks with Dr. Ron Petersen, Director of the Mayo Clinic Alzheimer's Disease Center, about the recent FDA approval of aducanumab for the treatment of Alzheimer disease.

Dr. Jason Crowell speaks with Dr. Steve Pearson, President of the Institute for Clinical and Economic Review, about the clinical and economic impact of aducanumab, a drug recently approved by the FDA for the treatment of Alzheimer disease.

The first segment features Dr. Stacey Clardy in conversation with 2021 Ted Burns Humanism in Neurology Award recipient Dr. John Quinlan. In the second part of the podcast, Dr. Andy Southerland discusses the risk of readmission following inpatient admission for reversible cerebral vasoconstriction syndrome with Dr. Santiago Ortega-Gutierrez.

In the first segment, Dr. Jeff Ratliff discusses primary care management for acute sciatica and physical therapy referrals with Dr. Julie Fritz. In the second part of the podcast, Dr. Andy Southerland talks with Dr. Amrou Sarraj about efficacy and safety of direct endovascular thrombectomy compared to bridging therapy in patients with large vessel occlusions.

This month's replay of past episodes showcases a selection of interviews by Drs. Jeff Burns, Jason Crowell, and Gregg Day on updates in Alzheimer's disease diagnostics and the impact of future therapies, featuring Drs. Michael Weiner, Randall Bateman, Erik Musiek, Joseph Therriault, and Yvette Sheline.

Dr. Alex Menze speaks with Prof. Antonio Belli about the role of salivary small non-coding RNAs in the diagnosis of sport-related concussion.

Dr. Stacey Clardy speaks with Dr. Petra Ijäs about the incidence of stroke during pregnancy or puerperium in Finland from 1987-2016. 

In the first segment, Dr. Jason Crowell discusses a natural history study of "pure" primary lateral sclerosis with Dr. Anhar Hassan. In the second part of the podcast, Dr. Andy Southerland talks with Dr. Roland Faigle about the assessment of critical care needs for patients with spontaneous intracerebral hemorrhage.

In the first segment, Dr. Andy Southerland talks with Dr. Mijail Serruya about developing a brain-machine interface for patients with stroke. In the second part of the podcast, Dr. Jason Crowell discusses the relationship between CAG repeat length and cognition in adult patients with Dr. Jordan Schultz. 

In the first segment, Dr. Alex Menze talks to Dr. Robert Stern about developing NINDS consensus diagnostic criteria for traumatic encephalopathy syndrome. In the second part of the podcast, Dr. Jason Crowell speaks with Dr. Adam de Havenon about five-year cost trends and utilization of neurologist-prescribed drugs for Medicare Part D beneficiaries.

This month's replay of past episodes features a selection of Neurology Minute segments in which Dr. Chris Boes discusses the history of neurology and the neurologic exam.

Dr. Jeff Burns speaks with Prof. Maria Eriksdotter about whether cholinesterase inhibitors are associated with slower cognitive decline and decreased mortality risk.